original ) (raw )Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance
Jean Pallandre , Jean-paul Remy-martin
Blood, 2010
View PDFchevron_right
The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy
M. Mráz
View PDFchevron_right
Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab
Stefanie Srock
Experimental Hematology, 2001
View PDFchevron_right
B Cell Receptor Immunogenetics in B Cell Lymphomas: Immunoglobulin Genes as Key to Ontogeny and Clinical Decision Making
Electra Sofou
Frontiers in Oncology
View PDFchevron_right
B-cell maturation and antibody responses in individuals carrying a mutated CD19 allele
Sevgi Pekcan
View PDFchevron_right
Response: common variable immunodeficiency patients with increased CD21-/lo B cells suffer from altered receptor editing and defective central B-cell tolerance
Eric Meffre
Blood, 2011
View PDFchevron_right
CD20 Antigen Density at Time of Presentation Is An Independent Predictor of Outcome in B-Cell Lymphoproliferative Disorders
Mohammad M Chisti
2008
View PDFchevron_right
Diffuse large B-cell lymphoma response to Rituximab-PmitCEBO regimen is not predicted by FcγRIIIa158 polymorphism
Adrian Tempescul
HVM Bioflux, 2015
View PDFchevron_right
Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations
Marie-paule Lefranc
The Journal of Pathology
View PDFchevron_right
The significance of serum anti- rituximab (anti-CD20 monoclonal antibody) antibodies in treatment response of patients with B- cells malignancy
Dr. Ahmed Mohammed Salih
Al-Kufa University Journal for Biology
View PDFchevron_right
Rituximab therapy and autoimmune disorders: Prospects for anti-B cell therapy
Gregg Silverman
Arthritis & Rheumatism, 2003
View PDFchevron_right
Anti-CD20 treatment for B-cell malignancies: current status and future directions
Candice Jamois
Expert Opinion on Biological Therapy
View PDFchevron_right
Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era
Thomas Habermann
Blood, 2008
View PDFchevron_right
Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies
Ira Gupta
Annals of the New York Academy of Sciences, 2012
View PDFchevron_right
Effects of rituximab therapy on B cell differentiation and depletion
piersante sestini
Clinical Rheumatology, 2020
View PDFchevron_right
Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach
Mathilde de Jong
PLOS ONE, 2018
View PDFchevron_right
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma
Mark Cragg
Blood Advances, 2020
View PDFchevron_right
Mutational landscape of B-cell post-transplant lymphoproliferative disorders
Alexandar Tzankov
British Journal of Haematology
View PDFchevron_right
B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies
Dimitar Efremov
Leukemia, 2014
View PDFchevron_right
Stereotyped B-cell receptors in the context of a diverse Brazilian series of chronic lymphocytic leukemia
Ricardo Bigni
Blood Cells, Molecules, and Diseases, 2021
View PDFchevron_right
Inherited genetic susceptibility to monoclonal B-cell lymphocytosis
D. Toniolo
Blood, 2010
View PDFchevron_right
Global expression profiling of CD10 + /CD19 + pre-B lymphoblasts from Hispanic B-ALL patients correlates with comparative TARGET database analysis
Alfonso Méndez Tenorio
Discover Oncology
View PDFchevron_right
Analysis of the B cell receptor repertoire in six immune-mediated diseases
Eoin McKinney
Nature, 2019
View PDFchevron_right
Advantages of targeting B cell receptor complex to treat B-cell derived autoimmune diseases and lymphomas
Jemal Adem
Molecular Immunology, 2017
View PDFchevron_right
Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia
Henrik Hjorth-hansen
Experimental Hematology, 2012
View PDFchevron_right
Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis
Tuna Mutis
Journal of Experimental Medicine, 2008
View PDFchevron_right
B cell tolerance: Putting the horse before the cart
Garnett Kelsoe
Arthritis & Rheumatism, 2011
View PDFchevron_right
Expression of CD20 in B Cell Precursor Acute Lymphoblastic Leukemia
Jeevan Kumar D M
Indian Journal of Hematology and Blood Transfusion, 2012
View PDFchevron_right
GA101 P329G LALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B cell depletion and antitumor activity
Kevin Brady
Haematologica, 2017
View PDFchevron_right
Molecular Analysis of Human Immunoglobulin Heavy Chain Variable Genes (IgVH) in Normal and Malignant B Cells
Rizgar Mageed
The American Journal of Pathology, 1998
View PDFchevron_right
Running title: Rituximab modulates CD20 from the B-cell surface
Mark Cragg
2010
View PDFchevron_right
Association of germline genetic variants in RFC, IL15 and VDR genes with minimal residual disease in pediatric B-cell precursor ALL
Monika Lejman
Scientific Reports, 2016
View PDFchevron_right
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
Chulin Sha
The Lancet Oncology, 2019
View PDFchevron_right